Paul McKenzie

Paul McKenzie leads CSL Limited, Australia's most valuable company and the global leader in blood plasma-derived therapeutics. CSL operates the world's largest plasma collection network — over 300 donation centers primarily in the United States — and fractionates the collected plasma into a range of life-saving therapies at manufacturing facilities across the globe. CSL's primary products include immunoglobulins (used to treat primary immunodeficiencies, autoimmune diseases, and neurological conditions — the largest and fastest-growing category), albumin (used in critical care and liver disease), and clotting factors (for hemophilia patients). The plasma therapeutics market has high barriers to entry: building a plasma collection network takes years and billions of dollars, the fractionation process is complex and heavily regulated, and supply is inherently constrained by the availability of willing donors. The 2022 acquisition of Vifor Pharma for approximately $12 billion expanded CSL into iron deficiency treatments and nephrology, adding the Ferinject/Injectafer iron therapy franchise. CSL also operates CSL Seqirus, one of the world's largest influenza vaccine manufacturers. Key stock drivers include plasma collection volumes, immunoglobulin demand and pricing, Vifor integration and iron deficiency product growth, influenza vaccine market, R&D pipeline (including gene therapy for hemophilia), and the competitive dynamics with Takeda, Grifols, and other plasma fractionators.